Related Experiment Videos
Helicobacter pylori in Japan
T Shimoyama1, Y Fukuda, F Hirayama
1Internal Medicine 4, Hyogo College of Medicine, Japan.
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1996
Summary
Helicobacter pylori eradication therapy is recommended for peptic ulcers. Guidelines for Japanese patients include dual therapy with a proton pump inhibitor and antibiotic, with confirmation of H. pylori eradication post-treatment.
Area of Science:
- Gastroenterology
- Microbiology
- Oncology
Background:
- International consensus identifies Helicobacter pylori as a cause of peptic ulcer disease and a human carcinogen.
- H. pylori eradication therapy is recommended for all infected patients with peptic ulcers.
- Peptic ulcer disease presentation differs between Japanese and other populations.
Purpose of the Study:
- Develop clinical trial guidelines for gastric or duodenal ulcers associated with H. pylori in Japan.
- Outline H. pylori eradication therapy protocols.
- Investigate the H. pylori-gastric cancer relationship in Japan.
Main Methods:
- Diagnosis of H. pylori via culture, histology, urease test, or 13C-urea breath test.
- Eradication therapy typically involves dual therapy (proton pump inhibitor + antibiotic), potentially with a nitroimidazole.
- Confirmation of eradication using the same diagnostic methods 4-6 weeks post-treatment.
Main Results:
- Guidelines for H. pylori eradication therapy in Japanese patients with peptic ulcers have been established.
- Diagnostic and confirmation methods for H. pylori infection and eradication are defined.
- Research into the H. pylori and gastric cancer link, using animal models like the Mongolian gerbil, is ongoing.
Conclusions:
- H. pylori eradication therapy is crucial for peptic ulcer disease management.
- Specific guidelines are necessary due to population differences in disease presentation.
- Further research, including animal models, is vital for understanding H. pylori's role in gastric cancer.